Forte Biosciences (NASDAQ:FBRX) Trading 7.8% Higher – Should You Buy?

Posted by Brian Himes on Jul 19th, 2026

Forte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) shares traded up 7.8% on Friday . The stock traded as high as $47.94 and last traded at $48.5190. 268,175 shares changed hands during trading, a decline of 25% from the average daily volume of 358,363 shares. The stock had previously closed at $44.99.

Analyst Ratings Changes

Several equities analysts have recently weighed in on FBRX shares. Wall Street Zen upgraded Forte Biosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Forte Biosciences in a research report on Wednesday, July 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Forte Biosciences currently has an average rating of “Moderate Buy” and an average price target of $67.00.

Read Our Latest Stock Report on Forte Biosciences

Forte Biosciences Trading Up 8.6%

The stock has a market cap of $678.47 million, a price-to-earnings ratio of -10.53 and a beta of 2.85. The company’s fifty day moving average is $23.24 and its two-hundred day moving average is $26.86.

Forte Biosciences (NASDAQ:FBRX – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.08). Analysts predict that Forte Biosciences, Inc. will post -4.27 EPS for the current year.

Hedge Funds Weigh In On Forte Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FBRX. Global Retirement Partners LLC acquired a new position in Forte Biosciences during the 4th quarter worth $27,000. Bank of America Corp DE grew its holdings in Forte Biosciences by 5,641.8% during the 3rd quarter. Bank of America Corp DE now owns 3,158 shares of the company’s stock worth $47,000 after acquiring an additional 3,103 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in Forte Biosciences during the 3rd quarter worth approximately $161,000. Jane Street Group LLC purchased a new stake in shares of Forte Biosciences in the 4th quarter valued at approximately $228,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Forte Biosciences in the 3rd quarter valued at $234,000. Hedge funds and other institutional investors own 77.63% of the company’s stock.

About Forte Biosciences

(Get Free Report)

Forte Biosciences, Inc is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions.

The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis.